… ProQR Announces Publication on QR-110 for Leber’s Congenital … LEIDEN, the Netherlands, Aug. 01, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Adamson, Ph.D., senior vice president of ophthalmology for ProQR. “The ongoing clinical trial of QR-110 in patients with …
… ProQR Announces Preclinical Proof of Concept Data for AX-0810 … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … expression of the protein. A strong correlation (R 2 = 0.51) was reported between editing levels of NTCP and …
… ProQR Nominates Martin Maier, PhD to Board and Announces … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … be made available in the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under “Financials and …
ProQR Therapeutics today announced positive results from a planned analysis of its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations.
… ProQR Announces the Grant of two Key Patents, protecting … QR-010 for Cystic Fibrosis in the US and EU Key Updates ProQR received notice of grant for 2 key patents protecting … General Counsel and Chief Corporate Development Officer of ProQR. “We pursue a very aggressive patent strategy as our 16 …
… ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen … on ARVOLearn , ARVO’s online learning platform. Details of ProQR’s presentation are as follows: Presenter: Stephen R. Russell, MD, Professor and Director of Vitreoretinal …
… ProQR Announces Closing of Underwritten Public Offering of … and CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated … of $6.50 per share. All of the shares were offered by ProQR. The closing included the full exercise of the …
… ProQR Strengthens its Scientific Advisory Board with the … SAB. Science is at the core of everything we do at ProQR, and with this group as our key advisors we can be more … of success that will be invaluable as we advance our R&D programs and our broader RNA technologies, including the …